GlassScriptPhysician profile
Amy J Janetsky
NPI 1891244885
$3,314.63
in general payments reported to CMS, 2019-2025
32 companies · $677 in 2025
The $677 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $817 · 2023: $687 · 2024: $321 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.73 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.43 | 2021-2024 | |
| Astellas Pharma US INC | $420.13 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $307.57 | 2021-2025 | Aptima, Novasure, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $283.35 | 2021-2025 | |
| Organon LLC | $211.23 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $159.21 | 2021-2025 | Slynd |
| Novo Nordisk INC | $129.98 | 2021-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $127.79 | 2022-2025 | |
| Agile Therapeutics, INC. | $76.84 | 2021-2023 | Twirla |
| Avion Pharmaceuticals | $69.97 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $68.58 | 2021-2022 | |
| Millicent US INC | $68.05 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Mylan Pharmaceuticals INC. | $62.08 | 2021 | |
| Pfizer INC. | $55.72 | 2022 | |
| Daiichi Sankyo INC. | $48.42 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Channel Medsystems, INC. | $47.97 | 2022 | |
| Shield Therapeutics INC | $47.20 | 2022-2025 | |
| Therapeuticsmd, INC. | $43.13 | 2021 | |
| Coopersurgical, INC. | $38.36 | 2021-2024 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $37.84 | 2021-2023 | Gardasil 9 |
| Amgen INC. | $34.68 | 2021 | |
| Evofem Biosciences, INC. | $31.82 | 2021-2022 | |
| Exact Sciences Corporation | $31.36 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $29.53 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $28.59 | 2025 | Zurzuvae |
| Alydia Health | $26.80 | 2021 | |
| Becton, Dickinson and Company | $24.71 | 2025 | Bd Onclarity |
| Hologic INC | $20.91 | 2021 | |
| Medtronic, INC. | $18.22 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.13 | 2021 | |
| Optumhealth Care Solutions, LLC | $15.82 | 2023 | Zyno Solutions, Vivify Health Care Team Portal |
| Lupin INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Janetsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.